CN111374256A - Probiotic composition, use thereof, food and medicament - Google Patents
Probiotic composition, use thereof, food and medicament Download PDFInfo
- Publication number
- CN111374256A CN111374256A CN201811633592.5A CN201811633592A CN111374256A CN 111374256 A CN111374256 A CN 111374256A CN 201811633592 A CN201811633592 A CN 201811633592A CN 111374256 A CN111374256 A CN 111374256A
- Authority
- CN
- China
- Prior art keywords
- weight
- probiotic composition
- parts
- probiotic
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 51
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 51
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title abstract description 5
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 22
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 18
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 18
- 230000001603 reducing effect Effects 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 15
- 210000000577 adipose tissue Anatomy 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 7
- 229920001202 Inulin Polymers 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 229940009714 erythritol Drugs 0.000 claims description 7
- 235000019414 erythritol Nutrition 0.000 claims description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229960001866 silicon dioxide Drugs 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 description 5
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 4
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The invention provides a probiotic composition, application thereof, food and a medicament. The probiotic composition comprises: bifidobacterium breve; lactobacillus rhamnosus; and bifidobacterium lactis. The three bacteria in the probiotic composition can be synergistically symbiotic, and can promote growth and metabolism among the three bacteria, so that the probiotic composition can play a probiotic role in intestinal tracts, reduce inflammation in vivo and promote fat metabolism, thereby achieving the effects of losing weight and reducing fat.
Description
Technical Field
The invention relates to the field of food. In particular, the invention relates to probiotic compositions and uses thereof, food products and pharmaceutical products.
Background
With the change of aesthetic concept, a product capable of achieving the slimming purpose, namely a slimming product, is derived, and is deeply favored by consumers because the product can realize the quick slimming effect. However, most of the currently marketed weight-reducing products have extremely quick response, are easy to rebound after being stopped or eaten, and have great harm to human bodies.
The probiotics is a kind of active microorganisms beneficial to a host, and is a general term for active beneficial microorganisms which are planted in the intestinal tract and the reproductive system of a human body and can generate a health effect so as to improve the micro-ecological balance of the host and play a beneficial role. The probiotics can control the weight by influencing the appetite and metabolism of people, has small burden on the body and really realizes healthy weight reduction.
However, at present, diet foods or medicines containing probiotics still remain to be developed.
Disclosure of Invention
The present invention aims to solve at least to some extent at least one of the technical problems of the prior art.
In one aspect of the invention, a probiotic composition is presented. According to an embodiment of the invention, the probiotic composition comprises: bifidobacterium breve; lactobacillus rhamnosus; and bifidobacterium lactis.
Only a few probiotics were found to have body fat reducing effects. The inventor researches probiotics, and finds that not all the probiotics supported by the literature can achieve a good fat reducing effect in combination, for example, when the lactobacillus acidophilus, the lactobacillus reuteri or the bifidobacterium breve are eaten alone, the lactobacillus acidophilus, the lactobacillus reuteri or the bifidobacterium breve all have a certain fat reducing effect, and when the lactobacillus acidophilus, the lactobacillus reuteri or the bifidobacterium breve are eaten together, one of the three can be metabolized to generate bacteriostat, so that the growth and metabolism of other functional strains are influenced, and the efficacy is influenced. Furthermore, the inventor finds that three bacteria, namely bifidobacterium breve, lactobacillus rhamnosus and bifidobacterium lactis, can be synergistically symbiotic and mutually promote growth and metabolism, so that the bacteria can play a probiotic role in intestinal tracts, reduce inflammation in vivo and promote fat metabolism, thereby achieving the effects of losing weight and reducing fat.
According to an embodiment of the present invention, the probiotic composition described above may also have the following additional technical features:
according to an embodiment of the invention, the strain number of Bifidobacterium breve is B-3. The strains of Bifidobacterium breve currently studied are many, and the inventors found that Bifidobacterium breve B-3(Bifidobacterium breve B-3) has an effect of reducing visceral fat and subcutaneous fat.
According to an embodiment of the present invention, the strain number of lactobacillus rhamnosus is GG. The number of strains of Lactobacillus rhamnosus currently studied is large, and the inventors found that Lactobacillus rhamnosus (Lactobacillus rhamnosus GG) has the effects of coordinating the proliferation of bifidobacterium and reducing visceral fat.
According to an embodiment of the present invention, the strain number of bifidobacterium lactis is B420. The present inventors found that Bifidobacterium lactis (L Bifidobacterium lactis B420) has the effects of reducing body fat and controlling waist circumference.
It should be noted that the sources of the present invention, Bifidobacterium breve B-3, Lactobacillus rhamnosus GG and L Bifidobacterium lactis B420 are not strictly limited, and may be given or commercially available. According to an embodiment of the invention, Bifidobacterium breve B-3 is from Ribenston, Lactobacillus rhamnosus GG from DuPont, and Bifidobacterium lactis B420 from DuPont.
According to an embodiment of the invention, the probiotic composition comprises: 1-5 parts by weight of bifidobacterium breve; 0.4-2 parts by weight of lactobacillus rhamnosus; and 0.5-2 parts by weight of bifidobacterium lactis. The inventor obtains the probiotic adding proportion through a large number of experiments, so that the probiotic adding proportion, the probiotic adding proportion and the probiotic adding proportion can achieve a synergistic symbiotic effect, mutually promote growth and metabolism and achieve the purpose of extremely reducing body fat. If the content of one or more bacteria is excessive, other probiotics or intestinal flora is competitively inhibited from growing and metabolizing, so that the intestinal flora is disordered, the fat reducing effect is poor, the intestinal dysfunction is easy to cause, and the body health is influenced.
According to the embodiment of the invention, the mass ratio of the bifidobacterium breve to the lactobacillus rhamnosus to the bifidobacterium lactis is (20-30): (5-10): (10-15). The inventor finds that after the three bacteria are compounded according to the proportion, the three bacteria have a good synergistic symbiosis effect, promote growth and metabolism among the three bacteria and achieve the purpose of reducing body fat.
According to an embodiment of the invention, the probiotic composition further comprises: inulin, fructo-oligosaccharides, erythritol, maltodextrin and silicon dioxide. Inulin and fructo-oligosaccharide are used as prebiotics, can promote the proliferation of probiotics, are particularly suitable for bifidobacterium breve, lactobacillus rhamnosus and bifidobacterium lactis, can promote the growth and metabolism of the bifidobacterium breve, the lactobacillus rhamnosus and the bifidobacterium lactis, and achieve the purpose of extremely reducing body fat. Erythritol can provide suitable sweetness, and the product has good palatability, excellent mouthfeel, and low calorie. The maltodextrin can improve the stability of the product, delay the reduction of the number of the probiotics in the shelf life, and has good palatability and excellent taste. Silica mainly acts as an anti-caking agent, keeping the powder in an optimal free-flowing state, and is particularly suitable for solid beverages.
According to an embodiment of the invention, the probiotic composition further comprises: 30-60 parts by weight of inulin; 10-30 parts by weight of fructo-oligosaccharide; 30-60 parts by weight of erythritol; 30-60 parts by weight of maltodextrin; 1 to 5 parts by weight of silica; and 10-30 parts by weight of strawberry powder. The inventor obtains the better proportion through a large number of experiments, so that the growth and metabolism of the three probiotics can be further promoted, the probiotics can be played in intestinal tracts, internal inflammation is relieved, fat metabolism is promoted, body fat is reduced, and the effects of losing weight and lowering fat are achieved.
According to an embodiment of the invention, the probiotic composition comprises: 2.5 parts by weight of bifidobacterium breve; 0.8 parts by weight of lactobacillus rhamnosus; 1.3 parts by weight of bifidobacterium lactis; 60 parts by weight of inulin; 20 parts by weight of fructo-oligosaccharide; 15 parts by weight of strawberry powder; 39.4 parts by weight of erythritol; 60 parts by weight of maltodextrin; and 1 part by weight of silica. Therefore, the probiotic composition provided by the embodiment of the invention can play a probiotic role in intestinal tracts, reduce inflammation in vivo and promote fat metabolism, so that body fat is reduced, and the effects of losing weight and reducing fat are achieved.
In a further aspect of the invention, the present invention proposes the use of a probiotic composition as described above in the preparation of a food product or a pharmaceutical product. According to an embodiment of the invention, the food or pharmaceutical product is for reducing body fat. The probiotic composition can play a probiotic role in intestinal tracts, relieve inflammation in vivo and promote fat metabolism, so that body fat is reduced, and the effects of losing weight and reducing fat are achieved.
In yet another aspect of the invention, a food product is provided. According to an embodiment of the invention, the food product contains a probiotic composition as described above. Therefore, the food disclosed by the embodiment of the invention can play a probiotic role in intestinal tracts, relieve inflammation in vivo and promote fat metabolism, so that body fat is reduced, and the effects of losing weight and lowering fat are achieved.
According to an embodiment of the invention, the food product is a solid beverage.
In yet another aspect of the invention, a pharmaceutical product is provided. According to an embodiment of the invention, the pharmaceutical product contains a probiotic composition as described above. Therefore, the medicine provided by the embodiment of the invention can play a probiotic role in intestinal tracts, relieve inflammation in vivo and promote fat metabolism, so that body fat is reduced, and the effects of losing weight and lowering fat are achieved.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
fig. 1 shows a schematic diagram of changes in body weight and body fat according to an embodiment of the present invention.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Example 1
In this example, the probiotic composition was prepared according to the following method:
(1) weighing inulin, fructo-oligosaccharide, strawberry powder, maltodextrin and erythritol according to the formula amount in the table 1;
(2) mixing the components uniformly;
(3) adding Bifidobacterium lactis B420, Bifidobacterium breve B-3, Lactobacillus rhamnosus GG and silicon dioxide;
(4) mixing uniformly to obtain the product.
TABLE 1 formulation
Example 2
Efficacy testing was performed on the probiotic composition of example 1:
the study population is as follows: the experimental population selects BMI (24.0-30.0), body fat rate (22% -30% for men and 28% -35% for women) and a compliance population aged 25-50 years;
and (3) experimental design: randomized, control, double blind trial studies, lasting 30 days. All the test and control groups tested body weight and body fat rate on day 1 before administration of 1-1 and 1-5 compositions, every 6 days thereafter, and the final day as the end point for 30 days, which were recorded as 7 days, 14 days, 21 days and 30 days, respectively, to determine the final body weight and body fat change.
Grouping tests: trial group 12, taking the composition of preferred embodiment 1-1 times daily, 2g each time; 1-5 composition group 8 people, 1 time daily, 2g each time; the blank group 8 received placebo (maltodextrin) 1 time a day at 2g each time.
Evaluation indexes are as follows: the efficacy of the composition during trial and after dry prognosis was evaluated by changes in body weight and body fat, and the results are shown in fig. 1.
As shown in Table 2, the results indicate that the body weight and body fat of the blank control group slightly increased after the end of the test period, while the body weight and body fat of the composition 1-1 were significantly reduced after the end of the test period, which was also significantly better than that of the composition 1-5. Therefore, the composition which is tried to be taken 1-1 has a certain fat-reducing and weight-losing effect on the whole, and is a better formula.
TABLE 2 body weight and body fat changes
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A probiotic composition, comprising:
bifidobacterium breve;
lactobacillus rhamnosus; and
bifidobacterium lactis.
2. The probiotic composition according to claim 1, characterized in that the bifidobacterium breve has strain number B-3;
the strain number of the lactobacillus rhamnosus is GG;
the strain number of the bifidobacterium lactis is B420.
3. The probiotic composition according to claim 1, characterized in that it comprises:
1-5 parts by weight of bifidobacterium breve;
0.4-2 parts by weight of lactobacillus rhamnosus; and
0.5-2 parts by weight of bifidobacterium lactis.
4. The probiotic composition according to claim 3, characterized in that the mass ratio of Bifidobacterium breve, Lactobacillus rhamnosus and Bifidobacterium lactis is (20-30): (5-10): (10-15).
5. The probiotic composition according to claim 1, characterized in that it further comprises: inulin, fructo-oligosaccharides, erythritol, maltodextrin and silicon dioxide.
6. The probiotic composition according to claim 5, characterized in that it further comprises:
30-60 parts by weight of inulin;
10-30 parts by weight of fructo-oligosaccharide;
30-60 parts by weight of erythritol;
30-60 parts by weight of maltodextrin;
1 to 5 parts by weight of silica; and
10-30 parts of strawberry powder.
7. Use of a probiotic composition according to any one of claims 1 to 6, for the preparation of a food or pharmaceutical product for reducing body fat and/or body weight.
8. A food product comprising the probiotic composition of any one of claims 1 to 6.
9. The food product of claim 8, wherein the food product is a solid beverage.
10. A pharmaceutical product comprising the probiotic composition according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811633592.5A CN111374256A (en) | 2018-12-29 | 2018-12-29 | Probiotic composition, use thereof, food and medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811633592.5A CN111374256A (en) | 2018-12-29 | 2018-12-29 | Probiotic composition, use thereof, food and medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111374256A true CN111374256A (en) | 2020-07-07 |
Family
ID=71220509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811633592.5A Pending CN111374256A (en) | 2018-12-29 | 2018-12-29 | Probiotic composition, use thereof, food and medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111374256A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955741A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for weight control and application thereof |
| CN113197288A (en) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN115466687A (en) * | 2021-06-11 | 2022-12-13 | 浙江妙活氏生物科技有限公司 | Composition for reducing body fat content and body weight and application thereof |
| CN115486542A (en) * | 2022-09-14 | 2022-12-20 | 上海菌小宝健康科技有限公司 | Composite probiotic powder beneficial to lipid-lowering metabolism and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061871A1 (en) * | 2007-11-09 | 2009-05-14 | The Hershey Company | Multi-layered fondant containing chewing gum |
| CN101646445A (en) * | 2007-03-28 | 2010-02-10 | 雀巢产品技术援助有限公司 | Probiotics for reduction of risk of obesity |
| CN104664329A (en) * | 2015-03-04 | 2015-06-03 | 益点堂（上海）生物科技有限公司 | Sugar-free probiotics powder and preparation method thereof |
| WO2017178316A1 (en) * | 2016-04-14 | 2017-10-19 | Dupont Nutrition Biosciences Aps | Bifidobacteria for reducing food, energy and/or fat intake |
-
2018
- 2018-12-29 CN CN201811633592.5A patent/CN111374256A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646445A (en) * | 2007-03-28 | 2010-02-10 | 雀巢产品技术援助有限公司 | Probiotics for reduction of risk of obesity |
| WO2009061871A1 (en) * | 2007-11-09 | 2009-05-14 | The Hershey Company | Multi-layered fondant containing chewing gum |
| CN104664329A (en) * | 2015-03-04 | 2015-06-03 | 益点堂（上海）生物科技有限公司 | Sugar-free probiotics powder and preparation method thereof |
| WO2017178316A1 (en) * | 2016-04-14 | 2017-10-19 | Dupont Nutrition Biosciences Aps | Bifidobacteria for reducing food, energy and/or fat intake |
| CN109069554A (en) * | 2016-04-14 | 2018-12-21 | 杜邦营养生物科学有限公司 | For reducing the Bifidobacterium of food, energy and/or fat intake |
Non-Patent Citations (2)
| Title |
|---|
| MINAMI J: "Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomized controlled trial", 《JOURNAL OF NUTRITIONAL SCIENCE》, no. 4, 31 December 2015 (2015-12-31) * |
| 肖永良: "说说益生菌", 《饮食科学》, no. 12, 1 December 2016 (2016-12-01), pages 6 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955741A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for weight control and application thereof |
| CN111955741B (en) * | 2020-08-12 | 2022-11-11 | 量子高科(广东)生物有限公司 | Composition for weight control and application thereof |
| CN113197288A (en) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN113197288B (en) * | 2020-08-31 | 2023-05-09 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN115466687A (en) * | 2021-06-11 | 2022-12-13 | 浙江妙活氏生物科技有限公司 | Composition for reducing body fat content and body weight and application thereof |
| CN115486542A (en) * | 2022-09-14 | 2022-12-20 | 上海菌小宝健康科技有限公司 | Composite probiotic powder beneficial to lipid-lowering metabolism and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111374256A (en) | Probiotic composition, use thereof, food and medicament | |
| CA2292325C (en) | Symbiotic functional food | |
| Kolida et al. | Prebiotic effects of inulin and oligofructose | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| Stadler et al. | Optimization of a formulation containing viable lactic acid bacteria | |
| WO2007043563A1 (en) | Composition for improving intestinal flora | |
| Anzawa et al. | Effects of synbiotics containing Bifidobacterium animalis subsp. lactis GCL2505 and inulin on intestinal bifidobacteria: A randomized, placebo‐controlled, crossover study | |
| CN113826692A (en) | Probiotic solid beverage and preparation method thereof | |
| JP2016520305A (en) | Association of Lactonospirae bacteria and body weight in gastrointestinal microbiota | |
| SG191417A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to stress | |
| US10314867B2 (en) | Composition for reducing intestinal gas production | |
| SG191420A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to chronic stress | |
| CN111388510A (en) | Probiotic composition | |
| Tulk et al. | Daily consumption of a synbiotic yogurt decreases energy intake but does not improve gastrointestinal transit time: a double-blind, randomized, crossover study in healthy adults | |
| KR20210079312A (en) | Method of Lactobacillus plantarum TWK10 composition for improving inflammation or reducing body fat after exercise | |
| CN102186494A (en) | Whey and thymus function | |
| CN111466572A (en) | Probiotic powder with intestinal tract regulating function and preparation method thereof | |
| Glibowski et al. | Prebiotic and synbiotic foods | |
| Onyenweaku et al. | Research Article Health Benefits of Probiotics | |
| AU2012245002A1 (en) | Weight loss composition | |
| KR102226434B1 (en) | A mixed vegetable powder for promoting intestinal motility and a powdery food composition for improving intestinal health containing it as an active ingredient | |
| Tyagi | 9. Role of prebiotics and probiotics in immunity | |
| Kadam et al. | Probiotics and prebiotics in healthy ageing | |
| WO2023074709A1 (en) | Relaxation feeling improving agent, and functional food and quasi drug containing said relaxation feeling improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200707 |
|
| RJ01 | Rejection of invention patent application after publication |